Gantenerumab data presented at CTAD- ADDF statement

Written By :  Dr. Nandita Mohan
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-12-03 04:00 GMT   |   Update On 2022-12-03 04:00 GMT
Advertisement

The phase 3 trial results for lecanemab and gantenerumab presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference demonstrate why optimal treatment of Alzheimer's will require drugs that do more than clear amyloid plaques. While lecanemab had an effect on slowing cognitive decline and removing amyloid plaques in the brain, gantenerumab had neither effect.

This was a historic Clinical Trial on Alzheimer's Disease conference, reflecting tremendous progress in Alzheimer's research and drug development. There have been a lot of encouraging news, including the lecanemab results and clinical trial data from other classes of drugs that demonstrate the diversity of the pipeline. The mixed data shows that while anti-amyloids are a promising starting point, however, there will be need for a combination of drugs aimed at different targets.

The rapidly advancing drug pipeline is matched by ongoing breakthroughs in accessible and affordable diagnostic tools that can tell which underlying causes are at play in each person's Alzheimer's condition. Researchers are also making advances in the use of digital tools, including wearable devices and at home digital tests, to provide earlier-than-ever diagnosis of Alzheimer's, perhaps even before symptoms are evident.

Reference:

ADDF statement on gantenerumab data presented at CTAD; ALZHEIMER'S DRUG DISCOVERY FOUNDATION

Full View
Tags:    
Article Source : Alzheimer's Drug Discovery Foundation

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News